Biodefense Market Size, Share & Trends Report

Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2020 - 2027

  • Published Date: Sep, 2020
  • Base Year for Estimate: 2019
  • Report ID: 978-1-68038-313-3
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 100

Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Market Segmentation & Scope
                      1.1.1 Product
                      1.1.2 Regional Scope
                      1.1.3 Estimates And Forecast Timeline
                 1.2 Research Methodology
                 1.3 Information Procurement
                      1.3.1 Purchased Database
                      1.3.2 Gvr’s Internal Database
                      1.3.3 Secondary Sources
                      1.3.4 Primary Research
                      1.3.5 Details Of Primary Research
                 1.4 Information Or Data Analysis
                      1.4.1 Data Analysis Models
                 1.5 Market Formulation & Validation
                 1.6 Model Details
                      1.6.1 Commodity Flow Analysis (Model 1)
                 1.7 List Of Secondary Sources
                 1.8 List Of Primary Sources
                 1.9 List Of Abbreviations
                 1.10 Objectives
                      1.10.1 Objective - 1:
                      1.10.2 Objective - 2:
                      1.10.3 Objective - 3:
                      1.10.4 Objective - 4:
Chapter 2 Executive Summary
                 2.1 Market Outlook
Chapter 3 Biodefense Market: Variables, Trends, & Scope
                 3.1 Market Segmentation And Scope
                 3.2 Market Dynamics
                      3.2.1 Market Driver Analysis
                      3.2.2 Presence Of Favorable Government Initiatives In The U.S.
                          3.2.2.1 Biodefense Funding In Fy 2016 - 2019 By Federal Agency
                          3.2.2.2 Emergency Use Authorization Of Medical Products
                          3.2.2.3 Project Bioshield Act
                          3.2.2.4 Growing Investment From Private Players
                      3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
                      3.2.4 Market Restraint Analysis
                          3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
                 3.3 Penetration & Growth Prospect Mapping
                 3.4 Biodefense: Market Analysis Tools
                      3.4.1 Industry Analysis - Porter’s
                      3.4.2 Pestel Analysis
                 3.5 Biodefense Competitive Scenario, 2015
                      3.5.1 Biological Defense
                          3.5.1.1 Biological Defense: Product Pipeline
                      3.5.2 Chemical Defense
                          3.5.2.1 Chemical Defense: Product Pipeline
                      3.5.3 Nuclear/Radiological Defense
                          3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis
Chapter 4 Biodefense Market: Product Segment Analysis
                 4.1 Biodefense: Agent Market Share Analysis, 2019 & 2027
                 4.2 Anthrax
                      4.2.1 Market Estimates And Forecasts, 2016 - 2027 (USD Million)
                 4.3 Smallpox
                      4.3.1 Market Estimates And Forecasts, 2016 - 2027 (USD Million)
                 4.4 Botulism
                      4.4.1 Market Estimates And Forecasts, 2016 - 2027 (USD Million)
                 4.5 Radiation/Nuclear
                      4.5.1 Market Estimates And Forecasts, 2016 - 2027 (USD Million)
                      4.5.2 Others
                          4.5.2.1 Market Market, 2016 - 2027 (USD Million)
Chapter 5 Biodefense Market: Regional Analysis
                 5.1 Biodefense: Regional Market Share Analysis, 2019 & 2027
                 5.2 North America
                      5.2.1 North America Biodefense Market, 2016 - 2027 (USD Million)
                      5.2.2 U.S.
                          5.2.2.1 U.S. Biodefense Market, 2016 - 2027 (USD Million)
                      5.2.3 Canada
                          5.2.3.1 Canada Biodefense Market, 2016 - 2027 (USD Million)
                 5.3 Europe
                      5.3.1 Europe Biodefense Market, 2016 - 2027 (USD Million)
                      5.3.2 U.K.
                          5.3.2.1 U.K. Biodefense Market, 2016 - 2027 (USD Million)
                      5.3.3 Germany
                          5.3.3.1 Germany Biodefense Market, 2016 - 2027 (USD Million)
                      5.3.4 France
                          5.3.4.1 France Biodefense Market, 2016 - 2027 (USD Million)
                      5.3.5 Italy
                          5.3.5.1 Italy Biodefense Market, 2016 - 2027 (USD Million)
                      5.3.6 Spain
                          5.3.6.1 Spain Biodefense Market, 2016 - 2027 (USD Million)
                 5.4 Asia Pacific
                      5.4.1 Asia Pacific Biodefense Market, 2016 - 2027 (USD Million)
                      5.4.2 China
                          5.4.2.1 China Biodefense Market, 2016 - 2027 (USD Million)
                      5.4.3 India
                          5.4.3.1 India Biodefense Market, 2016 - 2027 (USD Million)
                      5.4.4 Japan
                          5.4.4.1 Japan Biodefense Market, 2016 - 2027 (USD Million)
                 5.5 Latin America
                      5.5.1 Latin America Biodefense Market, 2016 - 2027 (USD Million)
                      5.5.2 Brazil
                          5.5.2.1 Brazil Biodefense Market, 2016 - 2027 (USD Million)
                      5.5.3 Mexico
                          5.5.3.1 Mexico Biodefense Market, 2016 - 2027 (USD Million)
                      5.5.4 Argentina
                          5.5.4.1 Argentina Biodefense Market, 2016 - 2027 (USD Million)
                 5.6 Mea
                      5.6.1 Mea Biodefense Market, 2016 - 2027 (USD Million)
                      5.6.2 South Africa
                          5.6.2.1 South Africa Biodefense Market, 2016 - 2027 (USD Million)
Chapter 6 Company Profiles
                 6.1 Xoma Corporation
                      6.1.1 Company Overview
                      6.1.2 Financial Performance
                      6.1.3 Product Benchmarking
                      6.1.4 Strategic Initiatives
                 6.2 Altimmune, Inc.
                      6.2.1 Company Overview
                      6.2.2 Financial Performance
                      6.2.3 Product Benchmarking
                      6.2.4 Strategic Initiatives
                 6.3 Emergent Biosolutions Inc.
                      6.3.1 Company Overview
                      6.3.2 Financial Performance
                      6.3.3 Product Benchmarking
                      6.3.4 Strategic Initiatives
                 6.4 Dynavax Technologies Corporation
                      6.4.1company Overview
                      6.4.2 Financial Performance
                      6.4.3 Strategic Initiatives
                 6.5 Siga Technologies, Inc.
                      6.5.1 company Overview
                      6.5.2 Financial Performance
                      6.5.3 Product Benchmarking
                      6.5.4 Strategic Initiatives
                 6.6 Elusys Therapeutics, Inc.
                      6.6.1 company Overview
                      6.6.2 Financial Performance
                      6.6.3 Product Benchmarking
                      6.6.4 Strategic Initiatives
                 6.7 Ichor Medical Systems
                      6.7.1 Company Overview
                      6.7.2 Financial Performance
                      6.7.3 Product Benchmarking
                      6.7.4 Strategic Initiatives
                 6.8 Dynport Vaccine Company Llc
                      6.8.1 company Overview
                      6.8.2 Financial Performance
                      6.8.3 Product Benchmarking
                      6.8.4 Strategic Initiatives
                 6.9 Cleveland Biolabs
                      6.9.1 Company Overview
                      6.9.2 Financial Performance
                      6.9.3 Product Benchmarking
                      6.9.4 Strategic Initiatives
                 6.10 Bavarian Nordic
                      6.10.1 Company Overview
                      6.10.2 Financial Performance
                      6.10.3 Product Benchmarking
                      6.10.4 Strategic Initiatives
                 6.11 Ology Bioservices
                      6.11.1company Overview
                      6.11.2 Financial Performance
                      6.11.3 Product Benchmarking
                      6.11.4 Strategic Initiatives
                 6.12 Alnylam Pharmaceuticals, Inc.
                      6.12.1 Company Overview
                      6.12.2 Financial Performance
                      6.12.3 Product Benchmarking
                      6.12.4 Strategic Initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 U.S. government civilian biodefense funding, by agencies for the years 2017-2019 in USD Million.
Table 4 National Institutes of Health Funding for the years 2017-2019 in USD Million
Table 5 Travel Associated cases of Zika Virus in the U.S in 2019
Table 6 Ebola Funding to WHO, 2019


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Biodefense market snapshot (2019)
Fig. 10 Biodefense market segmentation
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Biodefense market product type outlook: Segment dashboard
Fig. 17 Biodefense market: Product movement analysis
Fig. 18 Anthrax market, 2016 - 2027 (USD Million)
Fig. 19 Smallpox market, 2016 - 2027 (USD Million)
Fig. 20 Botulism market, 2016 - 2027 (USD Million)
Fig. 21 Radiation/Nuclear market, 2016 - 2027 (USD Million)
Fig. 22 Others market, 2016 - 2027 (USD Million)
Fig. 23 Regional market: Key takeaways
Fig. 24 Regional outlook, 2019 & 2027
Fig. 25 North America market, 2016 - 2027 (USD Million)
Fig. 26 U.S. market, 2016 - 2027 (USD Million)
Fig. 27 Canada market, 2016 - 2027 (USD Million)
Fig. 28 Europe market, 2016 - 2027 (USD Million)
Fig. 29 U.K. market, 2016 - 2027 (USD Million)
Fig. 30 Germany market, 2016 - 2027 (USD Million)
Fig. 31 France market, 2016 - 2027 (USD Million)
Fig. 32 Italy market, 2016 - 2027 (USD Million)
Fig. 33 Spain market, 2016 - 2027 (USD Million)
Fig. 34 Asia Pacific market, 2016 - 2027 (USD Million)
Fig. 35 China market, 2016 - 2027 (USD Million)
Fig. 36 India market, 2016 - 2027 (USD Million)
Fig. 37 Japan market, 2016 - 2027 (USD Million)
Fig. 38 Latin America market, 2016 - 2027 (USD Million)
Fig. 39 Brazil market, 2016 - 2027 (USD Million)
Fig. 40 Mexico market, 2016 - 2027 (USD Million)
Fig. 41 Argentina market, 2016 - 2027 (USD Million)
Fig. 42 MEA market, 2016 - 2027 (USD Million)
Fig. 43 South Africa market, 2016 - 2027 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.